New Treatment Paradigms in Multiple Myeloma

EP. 1: Molecular Pathogenesis of Multiple Myeloma

January 12th 2016

EP. 2: Defining High-Risk Multiple Myeloma

January 12th 2016

EP. 3: Managing Smoldering Myeloma

January 12th 2016

EP. 4: Treatment Regimens for Transplant Ineligible Myeloma

January 12th 2016

EP. 5: Treating Multiple Myeloma in Elderly Populations

January 12th 2016

EP. 6: Transplant-Eligible Patients in Multiple Myeloma

January 12th 2016

EP. 7: Consolidation and Maintenance Therapy in Multiple Myeloma

January 12th 2016

EP. 8: Managing Relapsed Disease in Multiple Myeloma

January 12th 2016

EP. 9: Significance of the ENDEAVOR Trial in Multiple Myeloma

January 12th 2016

EP. 10: Elotuzumab and Ixazomib in Multiple Myeloma

January 12th 2016

EP. 11: Applying New Multiple Myeloma Agents to Practice

January 12th 2016

EP. 12: Using Pomalidomide in Multiple Myeloma

January 12th 2016

EP. 13: FDA Labels of New Multiple Myeloma Agents

January 12th 2016

EP. 14: Potential Role of Daratumumab in Multiple Myeloma

January 12th 2016

EP. 15: Latest Advances in Multiple Myeloma Treatment

January 12th 2016

EP. 16: Continuing Anti PD-1 Therapy Beyond RECIST Progression

January 12th 2016